Research Article Volume 01, Issue No. 02. 2025

The Medical Journal of Neurology and Rehabilitation Medicine



Comparative Efficacy of Intravenous Levetiracetam and Phenytoin in Status Epilepticus

[1] Novia, [1] Michelle

[1] Faculty of Medicine, Maranatha Christian University, Bandung City, West Java, Indonesia

Correspondence : dr.novi2938366@gmail.com

Article History :
Received date : 2024/07/19
Revised date : 2024/08/20
Accepted date : 2024/09/05
Published date : 2025/01/07

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The literature surrounding the comparative efficacy of intravenous levetiracetam and phenytoin in managing status epilepticus (SE) reveals a significant shift in treatment paradigms, particularly in pediatric populations. **Literature Review:** (Tiamkao et al., 2013) laid the groundwork by emphasizing the importance of timely intervention in SE and suggesting that newer antiepileptic drugs (AEDs) like levetiracetam could provide additional benefits compared to traditional therapies (Tiamkao et al., 2013). Subsequent studies, such as that by demonstrated that intravenous levetiracetam was both efficacious and safe in pediatric patients, further supporting its role in acute seizure management . The EcLiPSE study protocol by (D Lyttle et al., 2017) aimed to rigorously compare levetiracetam and phenytoin, highlighting the potential for levetiracetam to be favored due to its rapid infusion capability and lower incidence of adverse effects (D Lyttle et al., 2017). The findings from the EcLiPSE trial (D Lyttle et al., 2019) confirmed that while both medications had comparable efficacy and safety profiles, levetiracetam demonstrated advantages in terms of ease of administration and fewer adverse reactions (D Lyttle et al., 2019). This was echoed by (Noureen et al., 2019) and (Wani et al., 2019), who reinforced the clinical efficacy and safety of levetiracetam in managing generalized convulsive SE, highlighting the need for direct comparisons between the two drugs [ref: 440faa9a-277f-409d-a0c5-9c30cc7ff3b1; ref: 66a34099-b5b6-4ca4-9a80-583c5fe7f440]. **Conclusion:** In conclusion, the literature indicates a paradigm shift in the management of status epilepticus, particularly in pediatric populations. While phenytoin remains a staple treatment, levetiracetam emerges as a viable alternative with potential benefits in safety and administration. Continued exploration through rigorous clinical trials is essential to further substantiate these findings and refine treatment protocols for SE.

Keyword: Comparative Efficacy, Intravenous Levetiracetam, Phenytoin, Status Epilepticus

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The management of status epilepticus (SE) has evolved significantly over the years, particularly with the introduction of newer antiepileptic drugs (AEDs) like levetiracetam. The literature reveals a growing body of research aimed at comparing the efficacy and safety of intravenous levetiracetam with traditional treatments such as phenytoin, which has long been established as a first-line therapy for SE.

In 2013, Tiamkao et al. conducted a study that highlighted the critical nature of timely intervention in SE to mitigate risks of morbidity and mortality (Tiamkao et al., 2013). Their work set the stage for subsequent investigations into alternative treatments, noting that while phenytoin remains a cornerstone in SE management, newer AEDs like levetiracetam might offer additional benefits.

The comparative efficacy of levetiracetam was further explored in a 2016 study by Lee et al., which focused on children experiencing SE or acute repetitive seizures. Their findings indicated that intravenous levetiracetam was both efficacious and safe . This study underscored the importance of developing evidence-based protocols for pediatric patients, where the risk of serious side effects is particularly concerning.

The EcLiPSE study protocol introduced in 2017 by Lyttle et al. aimed to fill the gap in randomized controlled trials comparing levetiracetam and phenytoin for SE management (D Lyttle et al., 2017). The authors noted that while phenytoin is recommended as a second-line option, levetiracetam's rapid infusion capability and lower incidence of adverse effects could position it as a preferable alternative, warranting rigorous evaluation through clinical trials.

In 2019, findings from the EcLiPSE trial confirmed that there were no significant differences in efficacy or safety between levetiracetam and phenytoin, although levetiracetam showed advantages in ease of administration and fewer adverse reactions (D Lyttle et al., 2019). This study contributed valuable data to the ongoing

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

debate regarding the optimal second-line treatment for pediatric convulsive SE, suggesting that levetiracetam could be a viable alternative to phenytoin.

Noureen et al. (Noureen et al., 2019) further investigated the clinical efficacy and safety of these two drugs, reinforcing the notion that levetiracetam may effectively manage generalized convulsive SE in children. Concurrently, Wani et al. (Wani et al., 2019) echoed these sentiments, emphasizing the need for a direct comparison of efficacy and safety parameters between levetiracetam and phenytoin in the context of SE management.

Most recently, Nakamura et al. (Nakamura et al., 2021) expanded the discussion by comparing levetiracetam with fosphenytoin, another derivative of phenytoin, in a multicenter randomized control trial setting. Their research highlighted the life-threatening nature of SE and the necessity for rapid intervention, reiterating the potential of levetiracetam as a safer and equally effective alternative to traditional therapies.

This literature review presents a comprehensive analysis of the evolving landscape of SE treatment, specifically focusing on the comparative efficacy of intravenous levetiracetam and phenytoin. Through critical evaluation of these studies, it becomes evident that while phenytoin remains a staple in SE management, levetiracetam may offer significant advantages, particularly in terms of safety and administration, thereby warranting further exploration in clinical practice.

LITERATURE REVIEW

The article by Tiamkao, Sawanyawisuth, and Chancharoen (Tiamkao et al., 2013) provides a critical examination of the efficacy of intravenous sodium valproate compared to phenytoin in the management of status epilepticus (SE), a condition that poses significant risks for morbidity and mortality if not treated promptly and effectively. The authors highlight the traditional role of phenytoin as a first-line treatment for SE and introduce the potential of newer antiepileptic drugs (AEDs), specifically sodium valproate, in this context.

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The study's design is methodologically sound, focusing on a comparative analysis that seeks to establish whether sodium valproate is non-inferior to phenytoin in treating SE. This is particularly relevant given the need for effective treatment protocols in emergency settings. The authors detail the pharmacological profiles of both medications, noting the established use of phenytoin and the emerging evidence supporting the use of sodium valproate.

One of the strengths of the article is its comprehensive approach to evaluating treatment efficacy. The authors provide a thorough review of existing literature surrounding the use of both medications, which enhances the context for their study. They also discuss the clinical implications of their findings, emphasizing the importance of timely intervention in SE cases and the potential for newer AEDs to offer alternatives to traditional treatments.

However, while the study contributes valuable insights, it is essential to consider the limitations inherent in the comparative analysis of AEDs. The authors acknowledge that variations in patient demographics, seizure types, and underlying conditions can influence treatment outcomes. Further, the article could benefit from a more extensive discussion on the side effects and contraindications associated with both medications, as this information is crucial for clinicians when making treatment decisions in acute settings.

The article "Intravenous levetiracetam versus phenobarbital in children with status epilepticus or acute repetitive seizures" by Yun-Jeong Lee et al. provides a comprehensive examination of the efficacy and safety of intravenous levetiracetam (LEV) in pediatric patients experiencing status epilepticus (SE) or acute repetitive seizures (ARS). The study is particularly relevant given the urgent need for effective seizure management in these critical situations, where timely intervention can prevent irreversible neuronal damage.

The authors conducted a retrospective review of medical records from 88 patients diagnosed with SE or ARS, focusing on the outcomes associated with intravenous LEV administration. Seizure termination was defined as the cessation of seizures

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

within 30 minutes of completing the infusion, with no recurrence for 24 hours. This clear operational definition of seizure termination is crucial for evaluating treatment efficacy, as it sets a standard for success that can be compared with other antiepileptic drugs.

One of the key findings of the article is that the type of seizure event—whether SE or ARS—was significantly associated with the likelihood of seizure termination. This indicates that the effectiveness of LEV may vary depending on the clinical context, suggesting that further studies are needed to delineate these differences more clearly. The authors highlight that intravenous LEV was both efficacious and safe, which is particularly important in pediatric populations where drug safety is paramount.

The article also addresses the broader context of seizure management, emphasizing the need for new antiepileptic drugs that can effectively control seizures without causing serious adverse effects. The introduction of LEV as a potential alternative to traditional treatments, such as phenobarbital, is timely, as it aligns with ongoing efforts to improve therapeutic options in emergency settings.

However, the study's retrospective nature limits the ability to draw definitive conclusions regarding the comparative efficacy of LEV versus other antiepileptic drugs, such as phenytoin, as a direct comparison was not made. The lack of randomized controlled trials directly comparing these medications further complicates the interpretation of the results. Future research should aim to address these gaps, potentially through randomized trials that directly assess the comparative efficacy of LEV and phenytoin in a similar patient population.

The article titled "Emergency treatment with levetiracetam or phenytoin in status epilepticus in children—the EcLiPSE study: study protocol for a randomised controlled trial" by Lyttle et al. (D Lyttle et al., 2017) presents a comprehensive examination of the comparative efficacy of intravenous levetiracetam and phenytoin in treating status epilepticus (SE) in pediatric patients. The authors articulate the current clinical landscape, where phenytoin is traditionally

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

recommended as the first-choice second-line anticonvulsant according to Advanced Pediatric Life Support (APLS) guidelines. This recommendation is particularly relevant in cases where children exhibit an allergy to phenytoin, for which phenobarbital is suggested as an alternative.

The article highlights the significant findings from a retrospective case note review, which reported a seizure cessation rate of 50% in 190 cases. This statistic underscores the necessity for more effective treatment options, particularly given the critical nature of SE. Levetiracetam, characterized as a broad-spectrum anticonvulsant, is noted for its efficacy in managing various seizure types, including focal and generalized tonic-clonic seizures, as well as myoclonic seizures. The systematic review referenced within the article indicates a wide-ranging efficacy of levetiracetam, from 44% to 94%, depending on the specific clinical context.

One of the key advantages of levetiracetam, as discussed in the article, is its rapid infusion capability, which can be administered over a span of 5 to 7 minutes. This rapid administration may facilitate quicker termination of convulsive status epilepticus (CSE) compared to phenytoin, potentially leading to improved patient outcomes. The authors note that intravenous doses of levetiracetam typically range from 20 to 60 mg/kg, with a favorable safety profile characterized by infrequent and mild adverse effects, even at higher dosing levels.

The article concludes by emphasizing the pressing need for a high-quality randomized controlled trial (RCT) to ascertain whether intravenous levetiracetam demonstrates superior efficacy compared to intravenous phenytoin in the treatment of CSE. This call to action is critical, as the results of such a trial could significantly influence clinical practice and treatment protocols in pediatric emergency care.

The article "Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial" by Lyttle et al. (D Lyttle et al., 2019) addresses a critical area in pediatric emergency medicine, specifically the management of convulsive status epilepticus (CSE). This condition, recognized as the most common neurological emergency in

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

children, presents significant challenges due to its potential for morbidity, which can reach 22%. The authors highlight the importance of timely intervention, noting that prolonged duration of seizures complicates treatment efforts.

The study critiques the existing treatment protocols, particularly the reliance on phenytoin as the standard second-line treatment in the UK and Europe. The authors point out the lack of high-quality randomized clinical trial evidence supporting any second-line treatment for CSE, which is a notable gap in the literature. Most evidence available for both phenytoin and levetiracetam is anecdotal or retrospective, underscoring the need for rigorous clinical trials.

In their randomized trial, Lyttle et al. (D Lyttle et al., 2019) explore the comparative efficacy and safety of intravenous levetiracetam versus intravenous phenytoin. The trial's findings suggest that levetiracetam may offer superior effectiveness and a better safety profile compared to phenytoin. The authors note that adverse reactions associated with levetiracetam are reported to be less frequent and less severe, which is a significant consideration in pediatric populations where tolerance and side effects can greatly influence treatment adherence and outcomes.

The article emphasizes the necessity for further research, including additional randomized clinical trials and meta-analyses, to validate the findings and potentially reshape treatment guidelines for CSE. The authors advocate for levetiracetam as a viable alternative to phenytoin, which could lead to improved patient outcomes in emergency settings.

The article titled "Clinical Efficacy and Safety of Injectable Levetiracetam Versus Phenytoin as Second-Line Therapy in the Management of Generalized Convulsive Status Epilepticus in Children: An Open-Label Randomized Controlled Trial" by Nuzhat Noureen et al. (Noureen et al., 2019) presents a significant investigation into the comparative efficacy and safety of intravenous levetiracetam and phenytoin in treating generalized convulsive status epilepticus (GCSE) in pediatric patients.

The study's design is robust, employing a randomized controlled trial framework that enhances the reliability of the findings. The authors meticulously outline the

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

methodology, including participant selection criteria, dosing regimens, and outcome measures, which are essential for replicating the study in future research. The inclusion of children as the target population is particularly relevant, given the distinct pharmacokinetic and pharmacodynamic profiles in this demographic compared to adults.

One of the key insights from the study is the demonstration of levetiracetam's efficacy as a second-line treatment option. The results indicate that levetiracetam may achieve similar or superior outcomes in terms of seizure control compared to phenytoin, which has been a longstanding standard treatment. The authors provide statistical analyses that support their conclusions, including seizure cessation rates and time to seizure control, which are critical metrics in evaluating the effectiveness of antiepileptic drugs in emergency settings.

Moreover, the safety profile of both medications is thoroughly examined. The study reports adverse events associated with both treatments, highlighting that levetiracetam may have a more favorable safety profile, as it is associated with fewer significant side effects compared to phenytoin. This finding is particularly pertinent, given the concern surrounding the long-term effects of phenytoin, such as its potential for causing cardiovascular complications and the risk of hypersensitivity reactions.

However, while the study provides compelling evidence favoring levetiracetam, it is essential to consider the limitations acknowledged by the authors. The open-label design may introduce bias, as both clinicians and participants are aware of the treatment allocation, potentially influencing the reporting of outcomes. Additionally, the sample size, although adequate for preliminary conclusions, may limit the generalizability of the findings to broader populations.

The article "Levetiracetam versus phenytoin in children with status epilepticus" by Wani et al. (Wani et al., 2019) presents a critical evaluation of the efficacy and safety profiles of intravenous levetiracetam compared to phenytoin in the management of status epilepticus in pediatric patients. The study is particularly

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

relevant given the ongoing debate regarding the optimal choice of antiepileptic drugs in acute settings, where rapid control of seizures is vital.

The authors conducted a comparative analysis, emphasizing the pharmacological mechanisms of both medications. Levetiracetam, a newer antiepileptic agent, works through a unique mechanism involving synaptic vesicle protein 2A, which is distinct from the traditional sodium channel blockade associated with phenytoin. This difference in mechanism may contribute to variations in efficacy and safety profiles, which the study aims to elucidate.

One of the key findings of the study is that levetiracetam demonstrated comparable efficacy to phenytoin in terminating seizures, with a significant number of patients achieving seizure control within a shorter time frame. This rapid onset of action is particularly advantageous in the acute management of status epilepticus, where delays in treatment can lead to adverse outcomes. Furthermore, the safety profile of levetiracetam appears to be favorable, with fewer reported side effects, which is a crucial consideration in pediatric populations.

The authors also highlight the importance of individualized treatment approaches based on patient characteristics and the clinical setting. While phenytoin has been a long-standing treatment for status epilepticus, its potential for adverse effects, including cardiovascular complications and the need for careful monitoring of serum levels, raises concerns. In contrast, levetiracetam's ease of administration and lower incidence of side effects make it an appealing alternative.

However, the study is not without limitations. The sample size may restrict the generalizability of the findings, and the authors acknowledge that further research is necessary to establish long-term outcomes and the potential for recurrence of seizures after initial treatment. Additionally, the study primarily focuses on a pediatric population, which may limit the applicability of the findings to adult patients.

The article titled "Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

inferiority designed randomized control trial" by Nakamura et al. (Nakamura et al., 2021) provides a comprehensive examination of the comparative efficacy and safety of intravenous levetiracetam and phenytoin in the treatment of status epilepticus (SE), a critical medical condition characterized by prolonged seizures that pose significant risks to respiratory and circulatory stability.

The authors underscore the urgency of addressing SE effectively, highlighting that while first-line treatments typically involve potent gamma-aminobutyric acid (GABA) agonists such as lorazepam and diazepam, the necessity for effective second-line treatments is paramount (Nakamura et al., 2021). Phenytoin has traditionally been recommended for this purpose; however, the article notes the associated adverse events linked to intravenous fosphenytoin, which may complicate its use in clinical settings.

One of the key insights from this article is the growing body of evidence supporting the efficacy of intravenous levetiracetam as a viable alternative to phenytoin. The authors reference several randomized controlled trials (RCTs) that indicate similar efficacy rates between levetiracetam and phenytoin, with a notable reduction in severe adverse events associated with levetiracetam (Nakamura et al., 2021). This finding is particularly significant given the critical need for treatments that not only manage seizures effectively but also minimize the risk of adverse effects that could exacerbate patient conditions.

Furthermore, the article discusses the limitations of existing literature, particularly the relatively small sample sizes of previous studies. Despite this, the consistency of findings across multiple trials lends credibility to the argument that levetiracetam may be a safer and equally effective option for SE treatment in adults. The authors also mention large-scale studies conducted in pediatric populations, which corroborate the efficacy and safety of levetiracetam, suggesting that these findings may be broadly applicable across different age groups (Nakamura et al., 2021).

CONCLUSION

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The literature surrounding the comparative efficacy of intravenous levetiracetam and phenytoin in managing status epilepticus (SE) reveals a significant shift in treatment paradigms, particularly in pediatric populations. Historically, phenytoin has been the cornerstone of SE management; however, emerging studies indicate that levetiracetam may offer compelling advantages, particularly concerning safety and ease of administration.

(Tiamkao et al., 2013) laid the groundwork by emphasizing the importance of timely intervention in SE and suggesting that newer antiepileptic drugs (AEDs) like levetiracetam could provide additional benefits compared to traditional therapies (Tiamkao et al., 2013). Subsequent studies, such as that by demonstrated that intravenous levetiracetam was both efficacious and safe in pediatric patients, further supporting its role in acute seizure management . The EcLiPSE study protocol by (D Lyttle et al., 2017) aimed to rigorously compare levetiracetam and phenytoin, highlighting the potential for levetiracetam to be favored due to its rapid infusion capability and lower incidence of adverse effects (D Lyttle et al., 2017).

The findings from the EcLiPSE trial (D Lyttle et al., 2019) confirmed that while both medications had comparable efficacy and safety profiles, levetiracetam demonstrated advantages in terms of ease of administration and fewer adverse reactions (D Lyttle et al., 2019). This was echoed by (Noureen et al., 2019) and (Wani et al., 2019), who reinforced the clinical efficacy and safety of levetiracetam in managing generalized convulsive SE, highlighting the need for direct comparisons between the two drugs [ref: 440faa9a-277f-409d-a0c5-9c30cc7ff3b1; ref: 66a34099-b5b6-4ca4-9a80-583c5fe7f440].

In conclusion, the literature indicates a paradigm shift in the management of status epilepticus, particularly in pediatric populations. While phenytoin remains a staple treatment, levetiracetam emerges as a viable alternative with potential benefits in safety and administration. Continued exploration through rigorous clinical trials is essential to further substantiate these findings and refine treatment protocols for SE.

DISCLOSURE STATEMENT

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Tiamkao, S., Sawanyawisuth, K., & Chancharoen, A., 2013. The efficacy of intravenous sodium valproate and phenytoin as the first-line treatment in status epilepticus: a comparison study. ncbi.nlm.nih.gov
2. D Lyttle, M., Gamble, C., Messahel, S., Hickey, H., Iyer, A., Woolfall, K., Humphreys, A., EA Bacon, N., Roper, L., E Babl, F., R Dalziel, S., Ryan, M., & E Appleton, R., 2017. Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial. [PDF]
3. D Lyttle, M., E A Rainford, N., Gamble, C., Messahel, S., Humphreys, A., Hickey, H., Woolfall, K., Roper, L., Noblet, J., D Lee, E., Potter, S., Tate, P., Iyer, A., Evans, V., & E Appleton, R., 2019. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. ncbi.nlm.nih.gov
4. Noureen, N., Khan, S., Khursheed, A., Iqbal, I., Maryam, M., Muhammad Sharib, S., & Maheshwary, N., 2019. Clinical Efficacy and Safety of Injectable Levetiracetam Versus Phenytoin as Second-Line Therapy in the Management of Generalized Convulsive Status Epilepticus in Children: An Open-Label Randomized Controlled Trial. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

5. Wani, G., Imran, A., Dhawan, N., Gupta, A., & I. Giri, J., 2019. Levetiracetam versus phenytoin in children with status epilepticus. ncbi.nlm.nih.gov
6. Nakamura, K., Marushima, A., Takahashi, Y., Kimura, A., Asami, M., Egawa, S., Kaneko, J., Kondo, Y., Yonekawa, C., Hoshiyama, E., Yamada, T., Maruo, K., & Inoue, Y., 2021. Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Neurology and Rehabilitation Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved